Enhanced αSyn SAA

There is an enhanced αSyn-SAA protocol developed by Amprion scientists, as described in Ma et al (Lancet Neurol 2024; 23: 1225–37). The “Enhanced αSyn SAA” is covered by Amprion, Inc.’s U.S. Patent Nos. 11,079,396 and 11,959,927, foreign patents, and U.S. and foreign patents pending.  The protocol for this assay will be shared for research purposes and may only be used upon entering a limited, royalty-free, non-exclusive license directly with Amprion.